30224699|t|Propofol inhibits parthanatos via ROS-ER-calcium-mitochondria signal pathway in vivo and vitro.
30224699|a|Parthanatos is a new form of programmed cell death. It has been recognized to be critical in cerebral ischemia-reperfusion injury, and reactive oxygen species (ROS) can induce parthanatos. Recent studies found that propofol, a widely used intravenous anesthetic agent, has an inhibitory effect on ROS and has neuroprotective in many neurological diseases. However, the functional roles and mechanisms of propofol in parthanatos remain unclear. Here, we discovered that the ROS-ER-calcium-mitochondria signal pathway mediated parthanatos and the significance of propofol in parthanatos. Next, we found that ROS overproduction would cause endoplasmic reticulum (ER) calcium release, leading to mitochondria depolarization with the loss of mitochondrial membrane potential. Mitochondria depolarization caused mitochondria to release more ROS, which, in turn, contributed to parthanatos. Also, we found that propofol inhibited parthanatos through impeding ROS overproduction, calcium release from ER, and mitochondrial depolarization in parthanatos. Importantly, our results indicated that propofol protected cerebral ischemia-reperfusion via parthanatos suppression, amelioration of mitochondria, and ER swelling. Our findings provide new insights into the mechanisms of how ER and mitochondria contribute to parthanatos. Furthermore, our studies elucidated that propofol has a vital role in parthanatos prevention in vivo and in vitro, and propofol can be a promising therapeutic approach for nerve injury patients.
30224699	0	8	Propofol	Chemical	MESH:D015742
30224699	18	29	parthanatos	Disease	
30224699	34	37	ROS	Chemical	MESH:D017382
30224699	41	48	calcium	Chemical	MESH:D002118
30224699	96	107	Parthanatos	Disease	
30224699	189	225	cerebral ischemia-reperfusion injury	Disease	MESH:D015427
30224699	231	254	reactive oxygen species	Chemical	MESH:D017382
30224699	256	259	ROS	Chemical	MESH:D017382
30224699	272	283	parthanatos	Disease	
30224699	311	319	propofol	Chemical	MESH:D015742
30224699	393	396	ROS	Chemical	MESH:D017382
30224699	429	450	neurological diseases	Disease	MESH:D020271
30224699	500	508	propofol	Chemical	MESH:D015742
30224699	512	523	parthanatos	Disease	
30224699	569	572	ROS	Chemical	MESH:D017382
30224699	576	583	calcium	Chemical	MESH:D002118
30224699	621	632	parthanatos	Disease	
30224699	657	665	propofol	Chemical	MESH:D015742
30224699	669	680	parthanatos	Disease	
30224699	702	705	ROS	Chemical	MESH:D017382
30224699	760	767	calcium	Chemical	MESH:D002118
30224699	833	846	mitochondrial	Disease	MESH:D028361
30224699	931	934	ROS	Chemical	MESH:D017382
30224699	967	978	parthanatos	Disease	
30224699	1000	1008	propofol	Chemical	MESH:D015742
30224699	1019	1030	parthanatos	Disease	
30224699	1048	1051	ROS	Chemical	MESH:D017382
30224699	1068	1075	calcium	Chemical	MESH:D002118
30224699	1097	1110	mitochondrial	Disease	MESH:D028361
30224699	1129	1140	parthanatos	Disease	
30224699	1182	1190	propofol	Chemical	MESH:D015742
30224699	1201	1230	cerebral ischemia-reperfusion	Disease	MESH:D002545
30224699	1235	1246	parthanatos	Disease	
30224699	1294	1305	ER swelling	Disease	MESH:D008228
30224699	1402	1413	parthanatos	Disease	
30224699	1456	1464	propofol	Chemical	MESH:D015742
30224699	1485	1496	parthanatos	Disease	
30224699	1534	1542	propofol	Chemical	MESH:D015742
30224699	1587	1599	nerve injury	Disease	MESH:D000080902
30224699	1600	1608	patients	Species	9606
30224699	Negative_Correlation	MESH:D015742	MESH:D000080902
30224699	Negative_Correlation	MESH:D015742	MESH:D002545
30224699	Negative_Correlation	MESH:D015742	MESH:D008228
30224699	Negative_Correlation	MESH:D015742	MESH:D017382
30224699	Negative_Correlation	MESH:D015742	MESH:D028361
30224699	Negative_Correlation	MESH:D015742	MESH:D020271
30224699	Negative_Correlation	MESH:D002118	MESH:D015742
30224699	Positive_Correlation	MESH:D002118	MESH:D017382

